allosteric modulator

allosteric modulator

[¦a·lə¦stir·ik ′mäd·yə‚lād·ər]
(biochemistry)
Mentioned in ?
References in periodicals archive ?
ADX71441 is a potent, selective positive allosteric modulator (PAM) that potentiates GABA responses at the GABAB receptor.
Aphase 2a trial of the novel mglur5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in parkinson's disease.
Table 1 11 Pharmacological domains Acetylcholine Dopamine GABA Glutamate Histamine Ion channel Melatonin Norepinephrine Opioid Orexin Serotonin Table 2 9 Modes of action Enzyme inhibitor Enzyme modulator Ion channel blocker Neurotransmitters releaser Positive allosteric modulator Receptor agonist Receptor antagonist Receptor partial agonist Reuptake inhibitor
The so-called neurosteriod is an allosteric modulator of the GABAa (gamma-aminobutyric acid type A) receptors.
Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 (a7) nicotinic acetylcholine receptor.
The investigators showed further that the macrolide antibiotic clarithromycin, a negative allosteric modulator of GABA-A receptors, reduced sleepiness in patients with central hypersomnolence syndromes in a randomized, double-blind, crossover trial (Ann Neurol.
We showed that p,p'-DDT potentiates the maximum FSH-stimulated cAMP production by the FSHR and thus acts as a positive allosteric modulator.
In particular, they focus on potential beneficial effects of zolpidem, a positive allosteric modulator of GABAA receptors, on the motor symptoms of PD.
The company's lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor.
Calcimimetic agents act as an allosteric modulator, imitating the properties of extracellular calcium activating the calcium-sensitive receptor on parathyroid cells.
During the study, the researchers conducted trials with the help og potential drug candidate ADX10059, a negative mGluR5 allosteric modulator.
Brexanolone (SAGE-547) is an allosteric modulator of both synaptic and extrasynaptic GABAA receptors.